Monopar Therapeutics (MNPR) Shares Outstanding (Weighted Average): 2016-2024
Historic Shares Outstanding (Weighted Average) for Monopar Therapeutics (MNPR) over the last 9 years, with Dec 2024 value amounting to $6.1 million.
- Monopar Therapeutics' Shares Outstanding (Weighted Average) rose 15.55% to $2.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was $2.1 million, marking a year-over-year increase of 15.55%. This contributed to the annual value of $6.1 million for FY2024, which is 105.58% up from last year.
- Latest data reveals that Monopar Therapeutics reported Shares Outstanding (Weighted Average) of $6.1 million as of FY2024, which was up 105.58% from $3.0 million recorded in FY2023.
- Over the past 5 years, Monopar Therapeutics' Shares Outstanding (Weighted Average) peaked at $6.1 million during FY2024, and registered a low of $2.3 million during FY2020.
- Over the past 3 years, Monopar Therapeutics' median Shares Outstanding (Weighted Average) value was $3.0 million (recorded in 2023), while the average stood at $3.9 million.
- Data for Monopar Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 105.58% (in 2024) over the last 5 years.
- Yearly analysis of 5 years shows Monopar Therapeutics' Shares Outstanding (Weighted Average) stood at $2.3 million in 2020, then grew by 9.94% to $2.5 million in 2021, then grew by 2.11% to $2.6 million in 2022, then increased by 15.64% to $3.0 million in 2023, then soared by 105.58% to $6.1 million in 2024.